Dopamine D2/3 receptor antagonism reduces activity-based anorexia

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Anorexia nervosa (AN) is a severe eating disorder with psychological and physiological components.
• Activity-based anorexia (ABA) in rodents models key aspects of AN, including weight loss, reduced food intake, and hyperactivity.
• The atypical antipsychotic olanzapine has shown promise in reducing both AN and ABA symptoms.

Purpose of the Study:

• To identify the specific pharmacological mechanisms of olanzapine that reduce ABA.
• To investigate the role of various neurotransmitter receptors in the ABA model.

Main Methods:

• Mice were treated with antagonists for serotonin (5-HT2A/2C, 5-HT3) and dopamine (D1-like, D2, D3, D2/3) receptors.
• Behavioral and physiological outcomes including food intake, body weight, wheel running, and survival were assessed in the ABA model.

Main Results:

• Dopamine D2/3 receptor antagonists (eticlopride, amisulpride) significantly reduced weight loss and hypophagia, and improved survival in ABA.
• Amisulpride demonstrated greater efficacy than olanzapine in mitigating ABA symptoms.
• Selective D2 or D3 receptor antagonists also increased survival, while other treatments were ineffective or detrimental.

Conclusions:

• Selective antagonism of dopamine D2 and/or D3 receptors robustly ameliorates ABA.
• Dopamine D2/3 and D3 receptor antagonists represent promising therapeutic avenues for anorexia nervosa.
• Further research into the mechanisms of D2/3 receptor regulation of ABA and clinical efficacy is warranted.